Tyra Biosciences, a Carlsbad, Calif.-based company discovering and developing new small molecule therapies targeting acquired resistance in oncology, raised $50M in Series A financing.
The round was co-led by Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group, and Canaan.
The company intends to use the funds to advance next-generation compounds targeting acquired resistance to current therapies towards clinical trials.
The team also includes:– Ronald V. Swanson, Ph.D., Chief Scientific Officer;– Robert L. Hudkins, Ph.D., Vice President, Chemistry;– Jane Arboleda, Associate Director of Cell Biology;– Esther van den Boom, Chief Financial Officer;– Jeffrey Hager, Ph.D., Scientific Advisor;– William Hahn, M.D.
Ph.D., Scientific Advisor; and– Jason Sheltzer, Ph.D, Scientific Advisor. | To read full story, visit https://startuparound.com/read/1578933007.779733/Tyra-Biosciences-Raises-USD-50M-in-Series-A-Funding?ref=audio_experience